MHRA Signs MoU with Russian Counterpart for Regulatory Cooperation on Medicines

February 1, 2019
Pharmaceutical Technology Editors

A Memorandum of Understanding (MoU) has been signed by the UK’s MHRA and the State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of the Russian Federation.

A Memorandum of Understanding (MoU) has been signed by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and the State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of the Russian Federation.

Through this MoU agreement, cooperation in the field of medicines regulation between the two nations will be increased. As reported on the UK government’s website, the MoU has been designed to establish mechanisms of cooperation that will expedite the following:

  • The exchange of information on medicines regulations

  • The exchange of safety information

  • Cooperation on good manufacturing practice (GMP) inspections

  • Collaboration on enforcement activities.

“Working in an increasingly global environment, the sharing of intelligence between medicines regulators is the cornerstone of protecting the health system worldwide,” explained Sam Atkinson, MHRA’s director of the Inspection, Enforcement and Standards Division. “Formalizing our already close working relationships with international counterparts helps facilitate this exchange of information. This makes it easier for us to track down criminals, promote good practices internationally, and identify emerging safety trends to protect public health.”

Source: gov.uk